Open access peer-reviewed Edited volume

Multiple Myeloma

An Overview

Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. Much insight has been gained into the molecular pathways that lead to myeloma and indeed much more remains to be done. The understanding of these pathways is closely linked to their therapeutic implications and is stressed upon in the initial chapters. Recently, the introduction of newer agents such as bortezomib, lenalidomide, thalidomide, liposomal doxorubicin, etc. has led to a flurry of trials aimed at testing various combinations in order to improve survival. Higher response rates observed with these agents have led to their integration into induction therapies. The role of various new therapies vis a vis transplantation has also been examined. Recent advances in the management of plasmacytomas , renal dysfunction, dentistry as well as mobilization of stem cells in the context of myeloma have also found exclusive mention. Since brevity is the soul of wit our attempt has been to present before the reader a comprehensive yet brief text on this important subject.

Read more >Order hardcopy
IntechOpen
Multiple MyelomaAn OverviewEdited by Ajay Gupta

Published: January 20th 2012

DOI: 10.5772/1240

ISBN: 978-953-307-768-0

Copyright year: 2012

Books open for chapter submissions

46853 Total Chapter Downloads

1 Crossref Citations

11 Web of Science Citations

19 Dimensions Citations

chaptersDownloads

Open access peer-reviewed

1. Proteasome Inhibitors in the Treatment of Multiple Myeloma

By Lisa J. Crawford and Alexandra E. Irvine

2218

Open access peer-reviewed

2. Regulatory Cells and Multiple Myeloma

By Karthick Raja Muthu Raja and Roman Hajek

1662

Open access peer-reviewed

3. Effects of Recombinant Human Tumor Necrosis Factor-α and Its Combination with Native Human Leukocyte Interferon-α on P3-X63- Ag8.653 Mouse Myeloma Cell Growth

By Andrej Plesničar, Gaj Vidmar, Borut Štabuc and Blanka Kores Plesničar

1544

Open access peer-reviewed

4. Cellular Immunotherapy Using Dendritic Cells Against Multiple Myeloma

By Je-Jung Lee, Youn-Kyung Lee and Thanh-Nhan Nguyen-Pham

1016

Open access peer-reviewed

5. Targeted Inhibition of Multiple Proinflammatory Signalling Pathways for the Prevention and Treatment of Multiple Myeloma

By Radhamani Kannaiyan, Rohit Surana, Eun Myoung Shin, Lalitha Ramachandran, Gautam Sethi and Alan Prem Kumar

1057

Open access peer-reviewed

6. The SUMOylation Pathway as a Potential Therapeutic Target in Multiple Myeloma

By James J. Driscoll

2093

Open access peer-reviewed

7. Therapeutic Approaches for Targeting Hypoxia- Inducible Factor in Multiple Myeloma

By Keita Kirito

1485

Open access peer-reviewed

8. Chapter 8 The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients

By Marie-Christine Kyrtsonis, Dimitrios Maltezas, Efstathios Koulieris, Katerina Bitsani, Ilias Pessach, Anna Efthymiou, Vassiliki Bartzis, Tatiana Tzenou and Panayiotis Panayiotidis

1211

Open access peer-reviewed

9. Solitary Plasmacytoma of Bone

By Jianru Xiao, Wending Huang, Xinghai Yang and Honglin Teng

3098

Open access peer-reviewed

10. Solitary Bone and Extramedullary Plasmacytoma

By Galina Salogub, Ekaterina Lokhmatova and Sergey Sozin

3986

Open access peer-reviewed

11. Multiple Myeloma and Dentistry

By Ajaz Shah, Suhail Latoo and Irshad Ahmad

20707

Open access peer-reviewed

12. Renal Disease in Multiple Myeloma

By Guray Saydam, Fahri Sahin and Hatice Demet Kiper

3833

Open access peer-reviewed

13. Stem Cell Mobılızatıon in Multıple Myeloma

By Şule Mine Bakanay and Taner Demirer

1882

Open access peer-reviewed

14. The Current Role of Stem Cell Transplantation in Multiple Myeloma

By Ajay Gupta

1061

Edited volume and chapters are indexed in

  • Worldcat
  • OpenAIRE
  • Google Scholar
  • AZ ebsco
  • Base
  • CNKI

Order a hardcopy of the Edited volume

Free shipping with DHL Express

Hardcover (ex. VAT)£140

Order now

Residents of European Union countries need to add a Book Value-Added Tax of 5%. Institutions and companies, registered as VAT taxable entities in their own EU member state, will not pay VAT by providing IntechOpen with their VAT registration number. This is made possible by the EU reverse charge method.

Special discount for IntechOpen contributors

All IntechOpen contributors are offered special discounts starting at 40% OFF available through your personal dashboard

Login and purchase